AS
Al-Batran, S-E.
2 yayın · 83 atıf · 2023–2023
Yayın
2
Atıf
83
Yıllar
1
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 11 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 72 |